Commercial-Scale ADC (Antibody-Drug Conjugate) CDMOs

· updated as new inspection, certificate, and trial data enters the platform

ADC (Antibody-Drug Conjugate) manufacturers on CDMO Signal: 7 listed, 7 with a Signal Score. Together they have 46 FDA inspections on file (including 17 NAI, 27 VAI and 2 OAI), 2 FDA warning letters and 111 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. The score does not measure HPAPI containment, linker-payload chemistry, or whether antibody, payload and conjugation sit on one site. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology. This page is the commercial-scale filter: a high Signal Score or a broad ClinicalTrials.gov footprint. It is not a list of approved commercial products.

7
CDMOs tracked
7
Fully scored
6
With FDA records
46
FDA inspections
111
EMA/MHRA GMP certs
2
Warning letters

Antibody-drug conjugates pair a targeting antibody with a cytotoxic payload via a chemical linker — a three-component process that crosses biologics, small-molecule, and HPAPI (high-potency API) disciplines. Manufacturing demands purpose-built containment (typically OEB-5), wet-chemistry linker-payload synthesis, and validated bioconjugation under GMP.

Selecting an ADC CDMO turns on commercial bioconjugation track record, containment level, the linker / payload chemistries already in their book of business (vc, mc, glucuronide; MMAE, MMAF, DM1, DM4, Dxd, calicheamicin, PBDs, etc.), drug-substance + drug-product capability, and clean FDA + EMA/MHRA inspections. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 17 NAI (no action), 27 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (34), Denmark (23), Italy (23), UNITED KINGDOM (22), Germany (13).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PR
Lexington, KY · Riverview, MI · Ahmedabad, IN
86.9 96.0 7 insp · 15 GMP 2026-02-13 · VAI — —
2
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
3
WB2
Shanghai, CN · Wuxi, CN
82.7 99.6 1 insp · 4 GMP 2026-07-03 · VAI — —
4
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
5
BP
Latina, Italy
79.5 100.0 1 insp · 15 GMP 2021-11-12 · VAI — —
6
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
79.5 100.0 — None on file Available —
7
Tampa, FL
Hiring · 311 open roles
76.1 77.3 24 insp · 39 GMP 2026-05-22 · VAI
Warning letter 2025-11-20
— —
How we score CDMOs →

What to evaluate in a ADC (Antibody-Drug Conjugate) CDMO

HPAPI containment
Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.
Linker-payload chemistry on file
Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.
Commercial bioconjugation track record
Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.
Integrated DS + DP
Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

ADC (Antibody-Drug Conjugate) CDMOs — Frequently Asked Questions

How many ADC (Antibody-Drug Conjugate) CDMOs have FDA inspection records?
CDMO Signal tracks 6 ADC (Antibody-Drug Conjugate) CDMOs with FDA inspection records and 111 EMA/MHRA GMP certificates across the group.
What's the difference between an ADC CDMO and a biologics CDMO?
A biologics CDMO makes the naked antibody (drug substance). An ADC CDMO additionally handles the cytotoxic payload synthesis and the bioconjugation step under HPAPI containment. Some large CDMOs (Lonza, Catalent) do both; others specialize in conjugation only and source the antibody from a biologics partner.
Which CDMOs have made commercially-approved ADCs?
Several CDMOs have commercial ADC track records. The rankings above show our scored ADC players — Lonza (Polivy, Padcev), Catalent (multi-program commercial conjugation), Piramal, AGC Biologics, Samsung Biologics, WuXi Biologics, Charles River — with FDA inspection and GMP detail per profile.
What HPAPI containment level should an ADC CDMO have?
OEB-5 (sub-microgram per cubic meter occupational exposure band) is the standard floor for handling MMAE, MMAF, DM1, DM4, Dxd, PBDs, and calicheamicin-class payloads. Some legacy payloads can run in OEB-4 but commercial work is OEB-5.
Related modalities
Biologics / mAb CDMOs Oligonucleotide / ASO CDMOs Recombinant Proteins CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins Gene Therapy Cell & Gene Therapy Viral Vector